Table 1 Characteristics of oncology drug approvals
|  |  | SAT n (%) n = 35 | RCT n (%) n = 66 |
|---|---|---|---|
Approval Year | 2016 | 4 (11.4) | 9 (13.6) |
2017 | 12 (34.3) | 16 (24.2) | |
2018 | 11 (31.4) | 22 (33.3) | |
2019 | 8 (22.9) | 19 (28.8) | |
Cancer Type | Bladder | 7 (20.0) | 1 (1.5) |
Breast | 2 (5.7) | 14 (21.2) | |
Colorectal | 2 (5.7) | 0 | |
Gastric | 1 (2.9) | 1 (1.5) | |
Head and Neck | 1 (2.9) | 2 (3.0) | |
Kidney | 0 | 7 (10.6) | |
Liver | 2 (5.7) | 4 (6.1) | |
Lung | 8 (22.9) | 15 (22.7) | |
Neuroendocrine tumors | 0 | 2 (3.0) | |
Ovarian | 2 (5.7) | 5 (7.6) | |
Prostate | 0 | 6 (9.1) | |
Skin | 3 (8.6) | 4 (6.1) | |
Tumor agnostic | 3 (8.6) | 0 | |
Other | 4 (11.4) | 5 (7.6) | |
Mechanism of Action | Antibody drug conjugate | 2 (5.7) | 1 (1.5) |
Androgen receptor inhibitor | 0 | 6 (9.1) | |
Immune checkpoint inhibitor | 18 (51.4) | 19 (28.8) | |
Molecularly-targeted drug | 11 (31.4) | 34 (51.5) | |
Combo | 3 (8.6) | 3 (4.5) | |
Other | 1 (2.9) | 3 (4.5) | |
Review Process | Breakthrough therapy | 22 (62.9) | 21 (31.8) |
Accelerated approval | 26 (74.3) | 3 (4.5) | |
Fast track | 2 (5.7) | 5 (7.6) | |
Priority review | 34 (97.1) | 46 (69.7) | |
Orphan | 10 (28.6) | 14 (21.2) |